Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pabst

Showing results (231-240 of 332) with videos related to

Pageof 34
Sort By:
Swiss Medical Weekly|October 28, 2024
Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims dataCaroline Arber, Gabriela Baerlocher, Yves Chalandon, et al.
Haematologica|December 15, 2015
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)Christoph Driessen, Marianne Kraus, Markus Joerger, et al.
Bone Marrow Transplantation|August 8, 2023
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMTJaime Sanz, Myriam Labopin, Thomas Pabst, et al.
Blood|March 17, 2012
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabineThomas Pabst, Edo Vellenga, Wim van Putten, et al.
The Lancet. Haematology|December 22, 2015
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysisJurjen Versluis, Carin L E Hazenberg, Jakob R Passweg, et al.
Cancer Cell|April 9, 2008
Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cellsPeggy Kirstetter, Mikkel B Schuster, Oksana Bereshchenko, et al.
Haematologica|January 2, 2016
Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large familyAnand Pathak, Katja Seipel, Alexander Pemov, et al.
Cancer|December 2, 2016
Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Norbert-Claude Gorin, Myriam Labopin, Tomasz Czerw, et al.
Haematologica|February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapyThomas Pabst, Norbert Vey, Lionel Adès, et al.
Hemasphere|November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study GroupAndreas Engert, Helen Goergen, Jana Markova, et al.
Pageof 34

Showing results (231-240 of 332) with videos related to

Sort By:
Pageof 34
Swiss Medical Weekly|October 28, 2024
Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims dataCaroline Arber, Gabriela Baerlocher, Yves Chalandon, et al.
Haematologica|December 15, 2015
Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)Christoph Driessen, Marianne Kraus, Markus Joerger, et al.
Bone Marrow Transplantation|August 8, 2023
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMTJaime Sanz, Myriam Labopin, Thomas Pabst, et al.
Blood|March 17, 2012
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabineThomas Pabst, Edo Vellenga, Wim van Putten, et al.
The Lancet. Haematology|December 22, 2015
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysisJurjen Versluis, Carin L E Hazenberg, Jakob R Passweg, et al.
Cancer Cell|April 9, 2008
Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cellsPeggy Kirstetter, Mikkel B Schuster, Oksana Bereshchenko, et al.
Haematologica|January 2, 2016
Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large familyAnand Pathak, Katja Seipel, Alexander Pemov, et al.
Cancer|December 2, 2016
Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Norbert-Claude Gorin, Myriam Labopin, Tomasz Czerw, et al.
Haematologica|February 13, 2023
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapyThomas Pabst, Norbert Vey, Lionel Adès, et al.
Hemasphere|November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study GroupAndreas Engert, Helen Goergen, Jana Markova, et al.
Pageof 34